J&J, Leg­end un­veil plans for Bel­gian cell ther­a­py man­u­fac­tur­ing fa­cil­i­ty as the part­ners await ap­proval for lead drug

In a race to get BC­MA CAR-T can­di­dates to mar­ket, J&J and Leg­end are adding a new EU man­u­fac­tur­ing fa­cil­i­ty in Bel­gium to the fold as they pre­pare to file.

The site is a part of a joint in­vest­ment with J&J to ex­pand its glob­al man­u­fac­tur­ing ca­pac­i­ty. It will de­vel­op and com­mer­cial­ize cil­ta-cel, al­so known as cil­ta­cab­ta­gene au­toleu­cel, an in­ves­ti­ga­tion­al ther­a­py for pa­tients with re­lapsed and re­frac­to­ry mul­ti­ple myelo­ma.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER